CDKN2A and invasive carcinoma: Other studies reported p16INK4a in 80% to 100% in invasive carcinoma, 45% to 100% in CIN2/3, and 0% to 15% in non-dysplasia (Bray et al., 2018; Kim et al., 2015; Volgareva et al., 2004; Sarma et al., 2017; Wentzensen et al., 2019).